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Pharmacological Approaches For the Management of Patients with Moderately 
Elevated Triglycerides (150-499 mg/dL) 
 
Abstract 
 
Hypertriglyceridemia, defined as serum triglyceride (TG) levels > 150 mg/dL, now affects 
over one-quarter of the U.S. adult population and is associated with an increased risk of 
atherosclerotic cardiovascular disease. Available guidelines for managing 
hypertriglyceridemia vary with respect to triglyceride thresholds and severity of disease. 
Lifestyle modifications and management of secondary causes (e.g., diabetes) remain the 
first step in managing hypertriglyceridemia, with pharmacotherapy reserved to reduce 
the risk of pancreatitis and/or further reduce TG levels. Several classes of lipid-lowering 
agents are available with variable TG-lowering efficacy. While there is no consensus 
regarding the choice of initial TG-lowering pharmacotherapy, there is general agreement 
that the decision depends on the degree of hypertriglyceridemia and atherosclerotic 
cardiovascular disease risk. This review will discuss available and emerging lipid-
lowering therapies for the management of moderately elevated TG, defined as TG 150-
499 mg/dL. 
 
 
 
Key Words: hypertriglyceridemia, guidelines, fibrates, omega-3 fatty acids, dyslipidemia 
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Abbreviations 
 
ACC= American College of Cardiology 
ACCORD= Action to Control Cardiovascular Risk in Diabetes 
AHA= American Heart Association 
AIM-HIGH= Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High 
Triglycerides: Impact on Global Health Outcomes 
ANGPTL= angiopoietin-like protein 
ApoC-III= apolipoprotein C-III 
ASCVD= atherosclerotic cardiovascular disease 
BAS= bile acid sequestrant 
DGAT= diacylglycerol acyltransferase 
ER= extended-release 
FIELD= Fenofibrate Intervention and Event Lowering in Diabetes 
FOURIER= Further Cardiovascular Outcomes Research with PCSK9 Inhibition in 
Subjects with Elevated Risk 
HDL-C= high-density lipoprotein cholesterol 
HHS= Helsinki Heart Study 
HPS2-THRIVE= Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of 
Vascular Events 
HR= hazard ratio 
LDL-C= low-density lipoprotein cholesterol 
LDL-R= low-density lipoprotein receptor 
Lp(a)= lipoprotein(a) 
LPL= Lipoprotein Lipase 
MACE= major adverse cardiovascular event 
MI= myocardial infarction 
NCEP ATP III= National Cholesterol Education Program Adult Treatment Panel III 
Non-HDL-C= non-high-density lipoprotein cholesterol 
O3FA= omega-3 fatty acid  
ODYSSEY= Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome 
During Treatment with Alirocumab 
PCSK9= Proprotein convertase subtilisin/kexin type 9 
PPAR= perioxisome proliferator-activated receptor 
TG = triglyceride 
US = United States 
VA-HIT= Veterans Affairs-High-Density Lipoprotein Cholesterol Intervention 
VLDL-C= very low-density lipoprotein cholesterol 
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Title:  
Pharmacological Approaches For the Management of Patients with Moderately Elevated 
Triglycerides (150-499 mg/dL) 
 
Introduction 
Targeting low-density lipoprotein cholesterol (LDL-C) with hydoxymethylglutaryl 
coenzymeA reductase (HMG-CoA) inhibitors, or statins, remains the primary therapy for 
preventing atherosclerotic cardiovascular disease (ASCVD); however, it is well 
established that statin-treated patients have a high-degree of residual risk.1 Possible 
explanations for this residual risk include inadequate reduction of LDL-C or the presence 
of mixed dyslipidemia. The latter is characterized by low levels of high-density lipoprotein 
cholesterol (HDL-C) and/or elevated triglycerides (TG); both of which are independently 
associated with increased ASCVD risk.2 
 
Elevated TG levels have long been linked to an increased risk for ASCVD, but the direct 
role TG play in the development and progression of atherosclerosis remains uncertain.2 
While average TG levels in the United States (US) have declined, the prevalence of 
hypertriglyceridemia still exceeds 25% in the US.3,4 This persistent hypertriglyceridemia 
is likely due to the increasing prevalence of secondary factors independently associated 
with hypertriglyceridemia, such as diabetes, obesity, metabolic syndrome, physical 
inactivity, and western diet. As such, lifestyle modifications, including physical activity, 
weight loss, and modification of dietary patterns should be provided to all patients with 
elevated TG. Additionally, genetic factors contribute to hypertriglyceridemia in >95% of 
individuals, which may necessitate the need for pharmacotherapy.4 
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The purpose of this review is to discuss current perspectives from national guidelines 
and the role of current and emerging lipid-lowering therapies for the management of 
moderately elevated TG (defined as TG values 150-499 mg/dL). 
 
 
National Guideline Recommendations 
 
The American Heart Association (AHA) released a Scientific Statement on Triglycerides 
and Cardiovascular Disease in 2011 to provide guidance on the importance of TG in 
assessing and managing ASCVD risk.2 While the definition for normal fasting TG 
remained <150 mg/dL, as recommended by the Adult Treatment Panel III of the National 
Cholesterol Education Program5 (NCEP ATP III), the authors suggested that optimal 
fasting TG levels should be <100 mg/dL. Significant emphasis was placed on initiation of 
intensive lifestyle interventions, such as eliminating trans fatty acids, reducing simple 
carbohydrates, implementing a Mediterranean-style diet, and weight loss of 5-10% body 
weight.2 Pharmacotherapy to lower TG was only recommended in individuals with TG 
≥500 mg/dL, without preference toward any specific TG-lowering therapy.2 
 
In 2012, the Endocrine Society Task Force developed Guidelines for the Evaluation and 
Treatment of Hypertriglyceridemia.6 While the Task Force again recognized TG <150 
mg/dL as normal, authors modified the NCEP ATP III TG classification to further 
differentiate between moderate, severe, and very severe hypertriglyceridemia (Table 1). 
The goal of this recommendation was to bring greater attention to very-high TG levels 
and the risk for acute pancreatitis. Non-HDL cholesterol (non-HDL-C) was identified as 
the treatment goal for patients with moderate hypertriglyceridemia, and maintaining TG 
<1000 mg/dL was the goal for patients with very severe hypertriglyceridemia. Citing a 
lack of conclusive evidence that TG-lowering therapies reduce ASCVD risk, 
pharmacotherapy was recommended only in those with severe hypertriglyceridemia 
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(>1000 mg/dL), with preference for fibrates over omega-3 fatty acids (O3FA) and niacin 
due to subgroup analysis from clinical trials suggesting reduced ASCVD risk with fibrate 
therapy in patients with TG >200 mg/dL. Lastly, statin monotherapy was not 
recommended for individuals with severe or very severe hypertriglyceridemia.6 
 
 
 
NCEP  
ATP III 
Normal 
<150 
Borderline 
150-199 
High 
200-499 
Very-high 
≥500  
AHA 2011 Normal 
<150 
Borderline 
150-199 
High 
200-499 
Very-high 
≥500  
Endocrine Society 
2012 
Normal 
<150 
Mild HTG 
150-199 
Moderate 
HTG 
200-999 
Severe 
HTG 
1000-1999 
Very severe 
HTG 
≥2000 
NLA 2014 Normal 
<150 
Borderline 
150-199 
High 
200-499 
Very-high 
≥500  
Table 1: Classification of fasting triglyceride concentration by guideline.2,5–7  
AHA= American Heart Association; HTG= hypertriglyceridemia; NCEP ATP III= National 
Cholesterol Education Program Adult Treatment Panel III; NLA= National Lipid 
Association. 
 
 
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) 
Guideline on the Treatment of Blood Cholesterol was not intended to be a 
comprehensive guideline.1 As such, few recommendations regarding 
hypertriglyceridemia management were reported except that patients with TG ≥500 
mg/dL receive evaluation for secondary causes. In light of limited randomized controlled 
trial evidence supporting the use of non-statin therapies in combination with statins, the 
guideline referred readers to the 2011 AHA Scientific Statement on Triglycerides.  
 
In 2014, the National Lipid Association (NLA) released recommendations based on a 
broader review of available literature than the 2013 ACC/AHA Guideline, which only 
evaluated evidence from randomized controlled trials.  As a result, the NLA expert panel 
embraced non-HDL-C as the primary target of therapy based on epidemiological studies 
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and pooled analyses of intervention studies that suggest non-HDL-C is superior to LDL-
C as a predictor of ASCVD risk.7 One explanation for the improved predictive value of 
non-HDL-C in patients with hypertriglyceridemia is that elevated TG levels impart greater 
atherogenic burden due to increased very low-density lipoprotein cholesterol (VLDL-C) 
levels and diminished plasma clearance of LDL-C via hepatic LDL receptors (LDL-R). In 
2015, a second NLA report provided comprehensive lifestyle recommendations for 
managing hypertriglyceridemia, including those recommended by the 2011 AHA 
statement.8 Nevertheless, the variability among these expert recommendations demand 
continuing discussion about appropriate management of hypertriglyceridemia.  
 
 
 
Lipid-Lowering Pharmacotherapy and Effects on Triglycerides 
 
Statins 
Statins reduce LDL-C by inhibiting HMG-CoA, which results in hepatic LDL-R up-
regulation to remove LDL-C from circulation.7 Because the LDL-lowering effect of statins 
is dose related, the 2013 ACC/AHA guidelines recommend higher statin doses (or 
intensity) in patients at greater risk for ASCVD.1  
 
The Individual Patient Meta-analysis of Statin Therapy in at Risk Groups: Effects of 
Rosuvastatin, Atorvastatin and Simvastatin (VOYAGER), examined dose-related 
changes in lipid parameters with three statins.9 Low-intensity simvastatin 10 mg reduced 
TG 9.3% from baseline, while high-intensity atorvastatin 80 mg lowered baseline TG 
levels by 25.0%. A subgroup analysis of VOYAGER examined dose-related statin effects 
in patients with baseline TG levels ≥177 mg/dL.10 Simvastatin 10 mg resulted in a 15.1% 
TG reduction, while atorvastatin 80 mg resulted in a 31.3% reduction in TG levels. These 
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results suggest that the TG-lowering effect of statins is dose related, with greater TG-
reductions seen in patients with higher baseline values. 
 
The benefits of statin therapy for reducing major adverse cardiovascular events (MACE) 
and ASCVD risk have been extensively described elsewhere, and are beyond the scope 
of this article.1,7  Due to their ability to lower both ASCVD risk and TG levels, several 
guidelines recommend statin therapy as an initial agent for patients with moderately 
elevated TG and increased ASCVD risk.2,5–7 
 
Lipid-lowering medication Triglyceride reduction (%) 
Fibrates 20 - 50 
Niacin 10 - 50 
Omega-3 fatty acids 20 - 50 
Statins 7 - 30 
Ezetimibe 5 - 10 
Bile acid sequestrants 0 (may increase up to 10%) 
PCSK9 inhibitors 0 - 17 
Table 2: Triglyceride lowering effect by medication class. 
 
Fibrates  
The fibric acid derivatives (fibrates including gemfibrozil and fenofibrate) are a class of 
lipid-lowering agents that significantly decrease TG (Table 2). Fibrates produce lipid-
lowering effects by activating the alpha subunit of perioxisome proliferator-activated 
receptors (PPARs).11 The PPAR-alpha belong to a superfamily of nuclear receptor 
proteins that act as transcription factors, leading to lipid-modifying gene expression. 
Activation of PPAR-alpha mediates TG reduction via three mechanisms: 1) suppressed 
production of lipoprotein lipase (LPL) inhibitor apolipoprotein C-III (ApoC-III); 2) reduced 
hepatic secretion of VLDL-C; and, 3) reduced hepatic TG production via beta-oxidation 
(Figure 1).11  
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A meta-analysis of 53 trials reported that fibrates reduce TG levels by 36% from baseline 
versus placebo (p<0.00001).12 The average TG-lowering effect of gemfibrozil was 48%, 
whereas fenofibrate reduced TG levels by 40%. Despite large reductions in TG, the 
impact of fibrate therapy on ASCVD outcomes has been variable. In the pre-statin era, 
trials such as the Helsinki Heart Study (HHS) and Veterans Affairs High-Density 
Lipoprotein Cholesterol Intervention Trial (VA-HIT) demonstrated reduced MACE with 
gemfibrozil versus placebo in patients with TG ≥160 mg/dL.13,14 In the Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) trial, no difference in the composite 
primary endpoint of MACE was observed in patients randomized to fenofibrate 200 
mg/day or placebo (5.9% versus 5.2%; p=0.16).15 However, a post-hoc analysis reported 
a trend toward reduction in the primary endpoint in patients with metabolic syndrome, 
including elevated TG levels (p=0.052).16 The lack of MACE reduction in the FIELD trial 
may be related to increased statin use in the placebo group (17%) compared with the 
fenofibrate (8%) group during the study period.15 In the Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) trial, adding fenofibrate to statin therapy significantly 
reduced TG levels by 13.5% versus placebo (p<0.0001) in patients with TG >150 mg/dL 
at baseline, but did not reduce the composite primary endpoint of MACE.17 Again, pre-
specified subgroup analysis suggested a trend toward benefit in patients with TG ≥204 
mg/dL and HDL-C <34 mg/dL randomized to fenofibrate versus placebo (p=0.057).17 
Furthermore, a recent post-trial follow-up to ACCORD showed that after an additional 
five years, fenofibrate use was associated with a 27% relative risk reduction (HR, 0.73; 
95% CI, 0.56-0.95) in the primary study outcome for the subgroup of patients with TG 
≥204 mg/dL and HDL-C <34 mg/dL.18  
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Figure 1: Targets of lipid-lowering medications (prefer color for on-line only) 
ApoB= apolipoprotein B; ApoC-III= apolipoprotein CIII; BA= bile acids; BAS= bile acid 
sequestrants; CE= cholesterol esters; CETP= cholesterylester transfer protein; DGAT= 
diglyceride acetyltransferase; FFA= free fatty acids; IDL= intermediate-density 
lipoprotein; HDL= high-density lipoprotein; LDL= low-density lipoprotein; LDL-R= low-
density lipoprotein receptor; LPL= lipoprotein lipase; NPC1L1= Niemann-Pick C1-Like1; 
O3FA= omega-3 fatty acids; PCSK9= proprotein convertase subtilisin/kexin type 9; TG= 
triglycerides; VLDL= very-low-density lipoprotein. 
 
Niacin  
Niacin, also known as nicotinic acid or vitamin B3, is a water-soluble vitamin which at 
high doses demonstrates the ability to lower total cholesterol, TG, VLDL-C, LDL-C, 
lipoprotein(a) [Lp(a)], while increasing HDL-C.19 Niacin decreases TG by inhibiting 
diacylglycerol acyltransferase (DGAT) 2, an enzyme that catalyzes the formation of TG 
from diacylglycerol and acyl-CoA.20 Niacin also inhibits lipolysis and subsequent release 
of TG into the circulation.20  
 
The Coronary Drug Project (CDP) was among the first clinical trials demonstrating 
niacin’s ability to reduce TG.  The CDP randomized male patients to one of six treatment 
IDL
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LDL
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arms, including niacin 3.0 g/day, with a primary aim to evaluate the efficacy of these 
therapies on long-term ASCVD risk.21 After a 5-year follow-up period, niacin reduced TG 
26.1% from baseline versus placebo. Additionally, a meta-analysis of 30 trials reported 
an average TG reduction of 20% from baseline.22 Furthermore, the TG-lowering effect 
was consistent for both intermediate-release and extended-release (ER) niacin, with 
reported 26% and 20% reduction, respectively.22  
 
Reduction in ASCVD events has been reported with niacin monotherapy, although 
before the discovery of statins. In the CDP trial, niacin did not significantly reduce the 
risk of death due to coronary artery disease, but did reduce risk of non-fatal myocardial 
infarction (MI) by 27% (8.9% in niacin and 12.2% in placebo). At 15 years of follow-up, 
nearly 9 years after trial end, mortality in the niacin group was 11% lower than placebo 
(52.0% versus 58.2%, p=0.0004).23 Recently, two trials have evaluated the benefit of 
niacin/statin combination therapy to reduce residual risk in patients with a history of 
ASCVD. In both the Atherothrombosis Intervention in Metabolic Syndrome with Low 
HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart 
Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events 
(HPS2-THRIVE) studies, adding ER niacin to statin therapy failed to reduce the primary 
endpoint of composite MACE in patients at LDL-C goal.24,25 However, higher rates of 
select adverse effects (glucose intolerance, gastrointestinal symptoms) were reported in 
the niacin treatment groups. 
 
Omega-3 Fatty Acids (O3FA) 
Omega-3 fatty acids (O3FA) are polyunsaturated fatty acids with the first double bond 
occurring in the omega-3 position of the carbon backbone.26 Currently there are three 
formulations of O3FA: eicosapentaenoic acid (EPA) ethyl ester, combination EPA and 
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docosahexaenoic acid (DHA) ethyl esters, and EPA/DHA carboxylic acids;27 however, 
insurance formularies will likely dictate which, if any, O3FA product is covered. There are 
a variety of over-the-counter O3FA supplements, but due to lack of regulation, may 
contain varying amounts and types of long-chain fatty acids.28 Although the exact 
mechanism is unknown, O3FAs may exert their TG-lowering effects similar to fibrates, 
including: increased hepatic beta-oxidation of fatty acids; increased LPL hydrolysis 
through activation of PPAR-alpha; and inhibition of ApoC-III.26  
 
In placebo-controlled trials including patients with TG levels 200-500 mg/dL, O3FA 
reduced TG by 22% from baseline compared to placebo.27 In a meta-analysis of 
placebo-controlled trials, O3FA demonstrated a 25-36% reduction in TG levels, with 
greater reductions observed in patients with baseline values ≥177 mg/dL versus <177 
mg/dL (34% versus 25%).29  
 
Multiple trials evaluating O3FA (at daily doses 1 to 2 g/day) to reduce cardiovascular risk 
in patients with ASCVD have produced conflicting results.30 In a trial of recent MI 
patients, 95% of whom were not receiving lipid-lowering therapy post-MI, O3FA lead to a 
10% reduction in the primary endpoint of death, non-fatal MI, and stroke versus placebo 
(p=0.048).27  However, several other studies in patients with ASCVD or at high risk were 
unable to demonstrate significant MACE benefit of O3FAs versus placebo.27 A recent 
AHA advisory statement suggests that O3FA supplementation is reasonable for 
secondary prevention of cardiovascular events in patients with prevalent ASCVD, and to 
reduce mortality and hospitalizations in patients with reduced ejection-fraction heart 
failure.30 
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Bile Acid Sequestrants (BAS) 
The BAS are non-soluble resins that bind bile acids in the intestines, removing bile acids 
from enterohepatic circulation, and ultimately leading to an up-regulation of LDL-R to 
remove serum cholesterol.31 Use of BAS is associated with 15-30% LDL-C reduction, 
and up to a 10% increase in TG values.7   
 
In one of the earliest primary-prevention trials, male patients with baseline LDL-C ≥190 
mg/dL and TG of 154 mg/dL were randomized to BAS (cholestyramine) or placebo for 
an average of 7.4 years.32 Treatment with cholestyramine significantly lowered both total 
cholesterol and LDL-C, and reduced the primary endpoint of MACE by 19% (p<0.05). 
Patients who received BAS had a greater increase in TG at 1-year (10.2%) compared to 
the placebo group (5.74%). By year seven, TG had increased by 17% to 182.9 mg/dL in 
the BAS group compared to an increase of 13.3% in the placebo group (significance not 
reported).32 Given the risk of increased TG, the 2013 ACC/AHA guideline recommends 
against use of BAS in patients with TG ≥ 300 mg/dL.1  
 
Ezetimibe 
Ezetimibe inhibits the Niemann-Pick C1-Like 1 transporter, thereby inhibiting absorption 
of cholesterol at the intestinal border.33 As anticipated from this mechanism of action, 
ezetimibe has little effect on TG. A meta-analysis of ezetimibe’s lipid-lowering effects 
found ezetimibe 10 mg daily to be associated with a mean 8% reduction in TG versus 
placebo (p<0.00001).34  Ezetimibe is indicated for use in combination with statin therapy 
for primary hyperlipidemia (to reduce total-C, LDL-C, Apo B, and non-HDL-C) and in 
combination with fenofibrate for patients with mixed dyslipidemia. Despite minimal TG-
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lowering effects, ezetimibe may be used in combination with other lipid-lowering agents 
to further reduce LDL-C, without increasing TG. 
 
Clinical ASCVD trials have primarily evaluated ezetimibe/statin combination versus statin 
monotherapy or placebo. The Improved Reduction of Outcomes: Vytorin Efficacy 
International (IMPROVE-IT) trial found that combination ezetimibe/simvastatin 
significantly reduced the composite MACE endpoint in patients with recent acute 
coronary syndrome compared to simvastatin monotherapy (32.7% vs. 34.7%, 
respectively, p=0.016).35 Whether ezetimibe monotherapy reduces ASCVD risk in 
patients with hypertriglyceridemia has not been evaluated by clinical trials. 
 
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I)  
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) prevents degradation 
of LDL-R, resulting in prolonged clearance of LDL-C from the plasma. Two humanized 
monoclonal antibodies (evolocumab, alirocumab) that inhibit PCSK9 are approved for 
LDL-C lowering in in patients with heterozygous familial hypercholesterolemia or clinical 
ASCVD, in addition to maximally tolerated statin therapy. Additionally, evolocumab is 
approved for homozygous familial hypercholesterolemia patients who require additional 
LDL-C lowering despite lipid-lowering therapy. 
 
A phase III study investigated the safety and efficacy of evolocumab in patients without 
current lipid-lowering therapy or previous statin intolerance.36 Patients received 
evolocumab subcutaneously, biweekly (140 mg) or monthly (420 mg), ezetimibe 10 mg 
plus placebo injection, or placebo for 12 weeks. Biweekly and monthly evolocumab 
treatment reduced TG 8.1% and 15.6% from baseline, respectively. Compared to 
placebo, monthly evolocumab significantly reduced TG 17.7% from baseline (p<0.001).36 
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More recently, a meta-analysis of 20 trials found that PCSK9-I treatment was associated 
with a significant 12.2% TG reduction (p<0.00001).37  
Recently, the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in 
Subjects With Elevated Risk (FOURIER) trial found that evolocumab significantly 
reduced the primary composite MACE endpoint compared to placebo (9.8% vs. 11.3%; 
p<0.001) over a median follow up period of 2.2 years.38 Results of a second ASCVD 
outcome trial, Evaluation of Cardiovascular Outcomes After an Acute Coronary 
Syndrome During Treatment With Alirocumab (ODYSSEY OUTCOMES), are expected 
in 2018. 
 
TG-Lowering Therapies in Development  
Volanesorsen (ISIS 304801) is an antisense oligonucleotide that targets ApoC-III mRNA 
in the liver, which regulates TG production via inhibition of LPL. Two Phase II trials have 
been completed in subjects with elevated TG 350-2000 mg/dL and familial 
chylomicronemia syndrome, an autosomal recessive disorder characterized by LPL 
deficiency.39,40 In both studies, volanesorsen reduced TG by as much as 80%. Given 
that individuals with ApoC-III loss-of-function variants are at lower ASCVD risk, there is 
potential for such therapies to translate to improved clinical outcomes. 
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Pemafibrate (K-877) is a highly-potent and selective antagonist of PPAR-alpha, which 
promotes macrophage cholesterol efflux to HDL, and reduces inflammatory markers.41  
In a phase II study, pemafibrate reduced TG by 43% and increased HDL-C 21%.42 As 
such, an international, multi-centered cardiovascular outcomes trial, PROMINENT, is in 
development with plans to randomize 10,000 high-risk patients with diabetes, with or 
without ASCVD, to pemafibrate or placebo, in addition to background high-intensity 
statin therapy.43 
 
Angiopoietin-like proteins (ANGTL) 3 and 4 are highly expressed in the liver and potent 
inhibitors of LPL, leading to decreased TG clearance. Importantly, individuals with an 
ANGPTL loss-of-function mutation have lower TG levels and are at lower risk of CVD. 
As such, there is great interest in developing inhibitors of ANGPTL proteins and early 
human clinical trials are ongoing.43–45 
 
Discussion  
Current guidelines addressing hypertriglyceridemia differ in their pharmacotherapy 
recommendations and choice of therapy seems to remain largely provider-dependent. 
Additionally, definitions of hypertriglyceridemia and TG thresholds for initiating 
pharmacotherapy to reduce the risk of ASCVD and acute pancreatitis vary. The 2012 
Endocrine Society’s recommendation to initiate TG-lowering pharmacotherapy for TG 
>1000 mg/dL was a departure from previous guidelines, which recommended TG-
lowering medications for TG >500 mg/dL to prevent pancreatitis.2,5 A recent cohort study 
reported that hypertriglyceridemia was associated with increased risks of acute 
pancreatitis and MI, with the highest event rates occurring in patients with TG ≥443 
mg/dL.46 Therefore, in accordance with previous guidelines, TG-lowering 
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pharmacotherapy should be initiated in patients with TG ≥500 mg/L to reduce risk of 
pancreatitis.  
 
When treating TG <500 mg/dL, most guidelines recommend using non-HDL-C as the 
primary treatment goal.5,7 In patients with moderately elevated TG (150-499 mg/dL), 
multiple lipid-lowering agents (fibrates, niacin, O3FA, and high-intensity statins) have 
proven ability to reduce TG by ≥ 30%; however, evidence supporting ASCVD risk 
reduction among non-statin therapies remains uncertain. Several guidelines recommend 
statin therapy as an initial agent for TG 150-499 mg/dL because of proven ASCVD risk 
reduction and respectable TG-lowering efficacy.2,5–7 The TG-lowering effect of statins 
appears dose-related, thus high-intensity statin should be initiated in most scenarios. 
Subgroup analysis suggests that statins exhibits greater TG-lowering effects in patients 
with higher baseline TGs (≥177 mg/dL) compared to patients with baseline TGs <177 
mg/dL.10  
A practical approach to treating moderately elevated TG may be to initiate high-intensity 
statin, followed by additional lipid-lowering agents as necessary to reach non-HDL-C 
goal. Additional agents to consider include fibrates, niacin, and O3FA because of larger 
TG-lowering efficacy than other non-statin agents. Fibrates have substantial TG-lowering 
ability and may be a preferred agent to add to statin therapy due to once-daily 
administration, favorable adverse effect profile, and generic product availability for most 
formulations. Preference should be given to fenofibrate products over gemfibrozil due to 
potential drug-drug interactions with several statins.47 While available clinical trials have 
not demonstrated additional ASCVD risk reduction with fenofibrate/statin combination, 
sub-group analysis suggests a benefit in patients with elevated TG.17,18 
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 In patients with TG 200-500 mg/dL, addition of O3FA to statin therapy further reduces 
TG 20-30% from baseline.27 Because O3FA are available as a dietary supplement, 
some patients may prefer this “natural” approach over prescription TG-lowering agents.  
Potential limitations of O3FA include multiple capsules required to achieve TG-lowering 
effects, and modest LDL-C increases with select O3FA products due to a shift toward 
larger, more buoyant LDL particles.48 Furthermore, no randomized trials to date have 
investigated ASCVD risk reduction when adding prescription strength O3FA to statin 
therapy, but two active clinical trials (REDUCE-IT and STRENGTH) are examining 
ASCVD outcomes in high-risk ASCVD patients with hypertriglyceridemia. These trials 
are expected to be completed in 2017 and 2019, respectively, and will shed more light 
on the impact of these agents in the context of modern treatment.27 
The support for niacin in combination with statins has diminished, likely due to increased 
risk of adverse effects and lack of ASCVD risk reduction reported by recent clinical 
trials.24,25 The American Diabetes Association (ADA) 2017 Standards of Care 
recommend against routine combination of niacin with statins, but that fibrate therapy 
may be considered in addition to statin therapy in men with TG ≥204 mg/dL and reduced 
HDL-C.49  The 2016 ACC Consensus Decision Pathway for non-statin therapies also 
recommend against combination of niacin with statin therapy; however, this update 
primarily focused on non-statin agents to further lower LDL-C and did not specifically 
address management of hypertriglyceridemia.50 Other lipid-lowering agents (BAS, 
ezetimibe, PCSK9-inhibitors) demonstrate greater efficacy in lowering LDL-C than TG, 
thus are preferred for patients receiving statin therapy who require further LDL-C 
reduction.50 Newer agents are currently being investigated in Phase 2 and 3 trials. 
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Conclusion 
While much progress has been made in reducing TG values among US adults, 
hypertriglyceridemia remains prevalent and contributes to increased risk of ASCVD and 
acute pancreatitis. Lifestyle interventions should be recommended in all patients with 
elevated TG levels, while selection of initial drug therapy depends on degree of 
hypertriglyceridemia. For moderately elevated TG (150-499 mg/dL), high-dose statin 
therapy should be preferred because of significant TG-lowering ability and ASCVD risk 
reduction benefits. If necessary, additional lipid-lowering agents may be added to reach 
non-HDL-C goals in effort to lower ASCVD risk. For individuals with TG levels ≥500 
mg/dL, non-statin therapies that significantly reduce TG are preferred initial agents to 
achieve TG <500 mg/dL and reduce the risk of acute pancreatitis. Ongoing trials 
evaluating the use of combination statin and TG-lowering therapies compared to statin 
monotherapy will shed light on the ongoing dilemma surrounding the treatment of 
moderately elevated TG to reduce ASCVD risk.  
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• Elevated triglycerides (150-499 mg/dL) are associated with increased risk of ASCVD 
• Pharmacologic treatment for elevated triglycerides varies by guideline 
• High-intensity statin therapy can significantly lower triglycerides and ASCVD risk  
• Additional non-statin agents may be necessary to reach non-HDL-C goals 
